These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25040659)

  • 1. A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.
    Grillberger R; Gruber B; Skalicky S; Schrenk G; Knöbl P; Plaimauer B; Turecek PL; Scheiflinger F; Rottensteiner H
    J Thromb Haemost; 2014 Sep; 12(9):1523-32. PubMed ID: 25040659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
    Shelat SG; Smith P; Ai J; Zheng XL
    J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
    Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
    Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.
    Plaimauer B; Schiviz A; Kaufmann S; Höllriegl W; Rottensteiner H; Scheiflinger F
    J Thromb Haemost; 2015 Nov; 13(11):2053-62. PubMed ID: 26340698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
    Zheng XL
    J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
    Postmus T; Graça NAG; Ferreira de Santana J; Ercig B; Langerhorst P; Luken B; Joly BS; Vanhoorelbeke K; Veyradier A; Coppo P; Voorberg J
    J Thromb Haemost; 2023 Dec; 21(12):3402-3413. PubMed ID: 37633643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTS-13 regulates platelet adhesion under flow. A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura.
    Shenkman B; Budde U; Angerhaus D; Lubetsky A; Savion N; Seligsohn U; Varon D
    Thromb Haemost; 2006 Aug; 96(2):160-6. PubMed ID: 16894459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.
    Muia J; Gao W; Haberichter SL; Dolatshahi L; Zhu J; Westfield LA; Covill SC; Friedman KD; Sadler JE
    J Thromb Haemost; 2013 Aug; 11(8):1511-8. PubMed ID: 23773695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.
    Joly B; Stepanian A; Hajage D; Thouzeau S; Capdenat S; Coppo P; Veyradier A
    Thromb Res; 2014 Nov; 134(5):1074-80. PubMed ID: 25262108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13.
    Kostousov V; Fehr J; Bombeli T
    Thromb Res; 2006; 118(6):723-31. PubMed ID: 16430944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.
    Kato S; Matsumoto M; Matsuyama T; Isonishi A; Hiura H; Fujimura Y
    Transfusion; 2006 Aug; 46(8):1444-52. PubMed ID: 16934083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Pos W; Luken BM; Kremer Hovinga JA; Turenhout EA; Scheiflinger F; Dong JF; Fijnheer R; Voorberg J
    J Thromb Haemost; 2009 Mar; 7(3):421-8. PubMed ID: 19054323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
    Starke R; Machin S; Scully M; Purdy G; Mackie I
    Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
    Shelat SG; Ai J; Zheng XL
    Semin Thromb Hemost; 2005 Dec; 31(6):659-72. PubMed ID: 16388417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
    Peyvandi F; Ferrari S; Lavoretano S; Canciani MT; Mannucci PM
    Br J Haematol; 2004 Nov; 127(4):433-9. PubMed ID: 15521921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
    Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ADAMT-13 in platelet adhesion in flow: methods for diagnosis of thrombotic thrombocytopenic purpura.
    Shenkman B
    Pathophysiol Haemost Thromb; 2006; 35(1-2):98-102. PubMed ID: 16855353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.
    Bettoni G; Palla R; Valsecchi C; Consonni D; Lotta LA; Trisolini SM; Mancini I; Musallam KM; Rosendaal FR; Peyvandi F
    J Thromb Haemost; 2012 Aug; 10(8):1556-65. PubMed ID: 22672482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.